Overall survival for PM cohort of 306 patients with AML by LSC17 score, continuous or discretized, as measured by research and clinical assays
| Overall survival . | Continuous scores univariate analysis (n = 306)* . | Discretized scores univariate analysis (n = 306)* . | ||
|---|---|---|---|---|
| Covariate . | Hazard ratio (95% CI)† . | P‡ . | Hazard ratio (95% CI)† . | P‡ . |
| High score (research) | 4.82 (2.98-7.78) | <.001 | 2.72 (2.04-3.63) | <.001 |
| High score (clinical) | 6.69 (4.31-10.39) | <.001 | 3.33 (2.48-4.47) | <.001 |
| Continuous scores multivariate analysis 1 (n = 283)* | Discretized scores multivariate analysis 1 (n = 283)* | |||
| High score (research) | 4.35 (2.42-7.82) | <.001 | 2.51 (1.79-3.51) | <.001 |
| Age | 1.00 (0.99-1.01) | .18 | 1.00 (0.99-1.01) | .29 |
| WBC count | 1.00 (1.00-1.00) | .001 | 1.00 (1.00-1.00) | .002 |
| Favorable cytogenetics | 0.46 (0.27-0.80) | .006 | 0.46 (0.26-0.79) | .005 |
| Adverse cytogenetics | 1.92 (1.28-2.88) | .001 | 1.91 (1.29-2.84) | .001 |
| Secondary/t-AML | 2.21 (1.49-3.28) | <.001 | 2.43 (1.64-3.60) | <.001 |
| Continuous scores multivariate analysis 2 (P < .001)§ | Discretized scores multivariate analysis 2 (P < .001)§ | |||
| High score (research) | 1.07 (0.38-2.97) | .88 | 1.55 (1.01-2.38) | .04 |
| High score (clinical) | 4.96 (1.94-12.6) | <.001 | 2.09 (1.36-3.21) | <.001 |
| Age | 1.01 (0.99-1.02) | .06 | 1.00 (0.99-1.01) | .15 |
| WBC count | 1.00 (1.00-1.00) | .01 | 1.00 (1.00-1.00) | .004 |
| Favorable cytogenetics | 0.52 (0.30-0.90) | .02 | 0.51 (0.29-0.88) | .01 |
| Adverse cytogenetics | 1.71 (1.14-2.55) | .008 | 1.73 (1.16-2.57) | .006 |
| Secondary/tAML | 2.13 (1.44-3.15) | <.001 | 2.26 (1.52-3.36) | <.001 |
| Overall survival . | Continuous scores univariate analysis (n = 306)* . | Discretized scores univariate analysis (n = 306)* . | ||
|---|---|---|---|---|
| Covariate . | Hazard ratio (95% CI)† . | P‡ . | Hazard ratio (95% CI)† . | P‡ . |
| High score (research) | 4.82 (2.98-7.78) | <.001 | 2.72 (2.04-3.63) | <.001 |
| High score (clinical) | 6.69 (4.31-10.39) | <.001 | 3.33 (2.48-4.47) | <.001 |
| Continuous scores multivariate analysis 1 (n = 283)* | Discretized scores multivariate analysis 1 (n = 283)* | |||
| High score (research) | 4.35 (2.42-7.82) | <.001 | 2.51 (1.79-3.51) | <.001 |
| Age | 1.00 (0.99-1.01) | .18 | 1.00 (0.99-1.01) | .29 |
| WBC count | 1.00 (1.00-1.00) | .001 | 1.00 (1.00-1.00) | .002 |
| Favorable cytogenetics | 0.46 (0.27-0.80) | .006 | 0.46 (0.26-0.79) | .005 |
| Adverse cytogenetics | 1.92 (1.28-2.88) | .001 | 1.91 (1.29-2.84) | .001 |
| Secondary/t-AML | 2.21 (1.49-3.28) | <.001 | 2.43 (1.64-3.60) | <.001 |
| Continuous scores multivariate analysis 2 (P < .001)§ | Discretized scores multivariate analysis 2 (P < .001)§ | |||
| High score (research) | 1.07 (0.38-2.97) | .88 | 1.55 (1.01-2.38) | .04 |
| High score (clinical) | 4.96 (1.94-12.6) | <.001 | 2.09 (1.36-3.21) | <.001 |
| Age | 1.01 (0.99-1.02) | .06 | 1.00 (0.99-1.01) | .15 |
| WBC count | 1.00 (1.00-1.00) | .01 | 1.00 (1.00-1.00) | .004 |
| Favorable cytogenetics | 0.52 (0.30-0.90) | .02 | 0.51 (0.29-0.88) | .01 |
| Adverse cytogenetics | 1.71 (1.14-2.55) | .008 | 1.73 (1.16-2.57) | .006 |
| Secondary/tAML | 2.13 (1.44-3.15) | <.001 | 2.26 (1.52-3.36) | <.001 |
CI, confidence interval; t-AML, therapy-related AML.
Number of patients with full clinical annotations are shown.
The 95% CI is displayed for each hazard ratio calculated by means of the multivariate Cox regression analysis.
The P-values were calculated by means of the Wald test.
Inclusion of LSC17 scores measured by the clinical assay in multivariate model 2 significantly improves predictions of patient outcomes compared with multivariate model 1. P-values were calculated by means of the likelihood ratio test.